AU2009319336B2 - Promoters for recombinant viral expression - Google Patents

Promoters for recombinant viral expression Download PDF

Info

Publication number
AU2009319336B2
AU2009319336B2 AU2009319336A AU2009319336A AU2009319336B2 AU 2009319336 B2 AU2009319336 B2 AU 2009319336B2 AU 2009319336 A AU2009319336 A AU 2009319336A AU 2009319336 A AU2009319336 A AU 2009319336A AU 2009319336 B2 AU2009319336 B2 AU 2009319336B2
Authority
AU
Australia
Prior art keywords
promoter
vector
nucleic acid
virus
ova
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2009319336A
Other languages
English (en)
Other versions
AU2009319336A1 (en
Inventor
Eva Felder
Christine Meisinger-Henschel
Robin Steigerwald
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bavarian Nordic AS
Original Assignee
Bavarian Nordic AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bavarian Nordic AS filed Critical Bavarian Nordic AS
Publication of AU2009319336A1 publication Critical patent/AU2009319336A1/en
Application granted granted Critical
Publication of AU2009319336B2 publication Critical patent/AU2009319336B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/023—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a poxvirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/60—Vectors comprising a special translation-regulating system from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2009319336A 2008-11-27 2009-11-27 Promoters for recombinant viral expression Active AU2009319336B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08020617.0 2008-11-27
EP08020617 2008-11-27
PCT/EP2009/008459 WO2010060632A1 (en) 2008-11-27 2009-11-27 Promoters for recombinant viral expression

Publications (2)

Publication Number Publication Date
AU2009319336A1 AU2009319336A1 (en) 2010-06-03
AU2009319336B2 true AU2009319336B2 (en) 2015-03-26

Family

ID=40419479

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009319336A Active AU2009319336B2 (en) 2008-11-27 2009-11-27 Promoters for recombinant viral expression

Country Status (8)

Country Link
US (2) US8772023B2 (enExample)
EP (1) EP2367944B1 (enExample)
JP (2) JP2012509678A (enExample)
AU (1) AU2009319336B2 (enExample)
CA (1) CA2741724C (enExample)
DK (1) DK2367944T3 (enExample)
NZ (1) NZ592082A (enExample)
WO (1) WO2010060632A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2618103T3 (es) 2008-11-21 2017-06-20 Bavarian Nordic A/S Vector que comprende múltiples secuencias de nucleótidos homólogas
EP2788021B1 (en) 2011-12-09 2017-01-18 Bavarian Nordic A/S Poxvirus vector for the expression of bacterial antigens linked to tetanus toxin fragment c
EP2864487B1 (en) 2012-06-22 2018-12-05 Bavarian Nordic A/S Poxviral vectors for low antibody response after a first priming immunization
PT2912183T (pt) 2012-10-28 2020-06-05 Bavarian Nordic As Promotor pr13.5 para respostas robustas de células t e anticorpos
KR20160140075A (ko) * 2015-05-29 2016-12-07 코오롱생명과학 주식회사 폭스바이러스 유래 프로모터 및 이를 포함하는 벡터
BR112017026649A2 (pt) * 2015-06-15 2018-08-28 Bavarian Nordic As vacina de vírus de febre aftosa (fmdv) de vírus vaccinia ankara modificado (mva) recombinante
FR3042121A1 (fr) 2015-10-08 2017-04-14 Jean-Marc Limacher Composition anti-tumorale
EP3407910B1 (en) 2016-01-29 2022-04-13 Bavarian Nordic A/S Recombinant modified vaccinia virus ankara (mva) equine encephalitis virus vaccine
US11052139B2 (en) 2016-09-28 2021-07-06 Bavarian Nordic A/S Compositions and methods for enhancing the stability of transgenes in poxviruses
WO2018091680A1 (en) 2016-11-18 2018-05-24 Transgene Sa Cowpox-based oncolytic vectors
ES2905478T3 (es) 2016-12-28 2022-04-08 Transgene Sa Virus oncolíticos y moléculas terapéuticas
EP3638302B1 (en) 2017-06-15 2024-03-13 Janssen Vaccines & Prevention B.V. Poxvirus vectors encoding hiv antigens, and methods of use thereof
WO2019020543A1 (en) 2017-07-28 2019-01-31 Transgene Sa ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS
JP7202362B2 (ja) 2017-08-24 2023-01-11 バヴァリアン・ノルディック・アクティーゼルスカブ 組み換えｍｖａ及び抗体の静脈内投与を用いた、がん治療のための併用療法
MX2020006471A (es) 2017-12-19 2020-09-22 Janssen Sciences Ireland Unlimited Co Metodos y composiciones para inducir una respuesta inmune contra el virus de hepatitis b (hbv).
WO2020011754A1 (en) 2018-07-09 2020-01-16 Transgene Chimeric vaccinia viruses
EP3860641A1 (en) 2018-10-05 2021-08-11 Bavarian Nordic A/S Combination therapy for treating cancer with an intravenous administration of a recombinant mva and an immune checkpoint antagonist or agonist
BR112021009856A8 (pt) 2018-11-20 2021-09-08 Bavarian Nordic As Terapia para tratamento do câncer com uma administração intratumoral e / ou intravenosa de um mva recombinante que codifica 4-1bbl (cd137l) e / ou cd40l
BR112022009798A2 (pt) 2019-11-20 2022-10-18 Bavarian Nordic As Vírus mva recombinante para administração intratumoral e/ou intravenosa para tratamento de câncer
US20220118081A1 (en) 2020-10-20 2022-04-21 Janssen Vaccines & Prevention B.V. HIV vaccine regimens
WO2023118508A1 (en) 2021-12-23 2023-06-29 Bavarian Nordic A/S Recombinant mva viruses for intraperitoneal administration for treating cancer
CA3240596A1 (en) 2021-12-23 2023-06-29 Cigdem ATAY LANGBEIN Therapy for modulating immune response with recombinant mva encoding il-12
CA3260357A1 (en) 2022-06-29 2024-01-04 Bavarian Nordic As RECOMBINANT MODIFIED ANKARA VIRUS (MVA) AND SMALL ACTIVATOR RNA (SPR) PRIMARY IMMUNIZATION REGIMEN
CN120380015A (zh) 2022-08-18 2025-07-25 特兰斯吉恩公司 嵌合痘病毒
AU2024208643A1 (en) 2023-01-12 2025-06-26 Bavarian Nordic A/S RECOMBINANT MODIFIED saRNA (VRP) FOR CANCER VACCINE
FR3160186A1 (fr) 2024-03-13 2025-09-19 Odimma Therapeutics Vecteur non-viral pour transcription augmentee

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992007579A1 (en) * 1990-11-06 1992-05-14 The Children's Medical Center Corporation Soluble mannose receptor peptides
US7314974B2 (en) * 2002-02-21 2008-01-01 Monsanto Technology, Llc Expression of microbial proteins in plants for production of plants with improved properties
US7312202B2 (en) * 2003-02-18 2007-12-25 Board Of Regents, The University Of Texas System Rationally designed and chemically synthesized promoter for genetic vaccine and gene therapy
DE602004009743T2 (de) * 2003-11-24 2008-08-28 Bavarian Nordic A/S Promotoren zur Expression in modifiziertem Vaccinia Virus Ankara
EP2864487B1 (en) * 2012-06-22 2018-12-05 Bavarian Nordic A/S Poxviral vectors for low antibody response after a first priming immunization

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Davison AJ et al, Journal of Molecular Biology, 1989, 210(4):771-784 *

Also Published As

Publication number Publication date
CA2741724C (en) 2016-10-04
US20140342403A1 (en) 2014-11-20
AU2009319336A1 (en) 2010-06-03
JP6291467B2 (ja) 2018-03-14
US8772023B2 (en) 2014-07-08
CA2741724A1 (en) 2010-06-03
JP2012509678A (ja) 2012-04-26
NZ592082A (en) 2013-03-28
EP2367944A1 (en) 2011-09-28
US20120121617A1 (en) 2012-05-17
WO2010060632A1 (en) 2010-06-03
EP2367944B1 (en) 2019-01-09
JP2016073297A (ja) 2016-05-12
DK2367944T3 (en) 2019-04-15

Similar Documents

Publication Publication Date Title
AU2009319336B2 (en) Promoters for recombinant viral expression
CA2751301C (en) Optimized early-late promoter combined with repeated vaccination favors cytotoxic t cell response against antigens in replication deficient recombinant virus vaccines
EP2912183B1 (en) Pr13.5 promoter for robust t-cell and antibody responses
JP7050044B2 (ja) ポックスウイルスベクターを用いて増強された免疫応答を誘導するための組成物及び方法ベクター
US11753652B2 (en) Cassette encoding a FPV/brachyury fusion protein
EP1567653B1 (en) Recombinant poxvirus comprising at least two cowpox ati promoters
US9163237B2 (en) Replication deficient recombinant viruses expressing antigens regulated by transcriptional control elements comprising multiple elements
EP1536015B1 (en) Promoters for expression in modified vaccinia virus ankara
JP2005525821A (ja) 牛痘ａｔｉプロモーターを用いた変異ワクシニアウイルスアンカラ中の遺伝子の発現
JP2005534326A (ja) アビポックスウイルスの力価を増加させるためのワクシニアウイルス宿主域遺伝子
EP1180155A1 (en) Vector for integration of heterologous sequences into poxviral genomes
HK1254405B (en) Promoters for enhancing expression in poxviruses
HK1226774A1 (en) Compositions and methods for inducing an enhanced immune response using poxvirus vectors
HK1226774B (en) Compositions and methods for inducing an enhanced immune response using poxvirus vectors

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)